Phase I Study of Osimertinib+Bevacizumab+Carboplatin and Pemetrexed for Untreated Patients With EGFR Mutation Advanced Non-squamous Non-Small Cell Lung Cancer With Concomitant Mutations.
Latest Information Update: 23 Aug 2022
At a glance
- Drugs Bevacizumab (Primary) ; Carboplatin (Primary) ; Osimertinib (Primary) ; Pemetrexed (Primary)
- Indications Non-small cell lung cancer
- Focus Therapeutic Use
Most Recent Events
- 23 Aug 2022 New trial record